nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT1A9—Mycophenolic acid—psoriasis	0.193	0.251	CbGbCtD
Tapentadol—UGT2B7—Mycophenolic acid—psoriasis	0.183	0.237	CbGbCtD
Tapentadol—UGT1A9—Mycophenolate mofetil—psoriasis	0.108	0.14	CbGbCtD
Tapentadol—UGT2B7—Mycophenolate mofetil—psoriasis	0.102	0.133	CbGbCtD
Tapentadol—CYP2D6—Hydroxyurea—psoriasis	0.0314	0.0408	CbGbCtD
Tapentadol—CYP2C19—Cholecalciferol—psoriasis	0.025	0.0325	CbGbCtD
Tapentadol—CYP2C9—Cholecalciferol—psoriasis	0.0208	0.027	CbGbCtD
Tapentadol—CYP2D6—Cholecalciferol—psoriasis	0.019	0.0247	CbGbCtD
Tapentadol—CYP2C19—Prednisone—psoriasis	0.0174	0.0225	CbGbCtD
Tapentadol—CYP2C19—Cyclosporine—psoriasis	0.0165	0.0214	CbGbCtD
Tapentadol—CYP2C9—Cyclosporine—psoriasis	0.0137	0.0178	CbGbCtD
Tapentadol—CYP2D6—Cyclosporine—psoriasis	0.0125	0.0162	CbGbCtD
Tapentadol—CYP2C19—Dexamethasone—psoriasis	0.0108	0.0141	CbGbCtD
Tapentadol—CYP2C9—Dexamethasone—psoriasis	0.00901	0.0117	CbGbCtD
Tapentadol—CYP2D6—Dexamethasone—psoriasis	0.00824	0.0107	CbGbCtD
Tapentadol—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00109	0.0484	CbGpPWpGaD
Tapentadol—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00101	0.0445	CbGpPWpGaD
Tapentadol—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000998	0.0441	CbGpPWpGaD
Tapentadol—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000939	0.0415	CbGpPWpGaD
Tapentadol—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000679	0.03	CbGpPWpGaD
Tapentadol—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000624	0.0276	CbGpPWpGaD
Tapentadol—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000619	0.0274	CbGpPWpGaD
Tapentadol—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.000318	0.0141	CbGpPWpGaD
Tapentadol—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.000313	0.0139	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000311	0.0138	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	0.000293	0.013	CbGpPWpGaD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000288	0.0127	CbGpPWpGaD
Tapentadol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000282	0.0125	CbGpPWpGaD
Tapentadol—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000278	0.0123	CbGpPWpGaD
Tapentadol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000259	0.0115	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.000258	0.0114	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	0.000257	0.0114	CbGpPWpGaD
Tapentadol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000257	0.0114	CbGpPWpGaD
Tapentadol—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000256	0.0113	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000255	0.0113	CbGpPWpGaD
Tapentadol—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000254	0.0112	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—IL13—psoriasis	0.000246	0.0109	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000233	0.0103	CbGpPWpGaD
Tapentadol—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000228	0.0101	CbGpPWpGaD
Tapentadol—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000218	0.00963	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	0.000217	0.00962	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—REL—psoriasis	0.00021	0.00929	CbGpPWpGaD
Tapentadol—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00021	0.00929	CbGpPWpGaD
Tapentadol—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000208	0.00921	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000205	0.00905	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000194	0.00859	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000181	0.00799	CbGpPWpGaD
Tapentadol—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	0.000181	0.00799	CbGpPWpGaD
Tapentadol—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.00018	0.00797	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—HCAR2—psoriasis	0.000178	0.00786	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.000177	0.00782	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000177	0.00782	CbGpPWpGaD
Tapentadol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000176	0.0078	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000174	0.0077	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000173	0.00765	CbGpPWpGaD
Tapentadol—Decreased appetite—Cyclosporine—psoriasis	0.000169	0.000816	CcSEcCtD
Tapentadol—Tachycardia—Hydrocortisone—psoriasis	0.000168	0.000814	CcSEcCtD
Tapentadol—Somnolence—Mycophenolate mofetil—psoriasis	0.000168	0.000814	CcSEcCtD
Tapentadol—Infestation—Methotrexate—psoriasis	0.000168	0.000813	CcSEcCtD
Tapentadol—Infestation NOS—Methotrexate—psoriasis	0.000168	0.000813	CcSEcCtD
Tapentadol—Depression—Methotrexate—psoriasis	0.000168	0.000811	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000167	0.00081	CcSEcCtD
Tapentadol—Skin disorder—Hydrocortisone—psoriasis	0.000167	0.00081	CcSEcCtD
Tapentadol—Fatigue—Cyclosporine—psoriasis	0.000167	0.000809	CcSEcCtD
Tapentadol—Hyperhidrosis—Hydrocortisone—psoriasis	0.000167	0.000806	CcSEcCtD
Tapentadol—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000167	0.000806	CcSEcCtD
Tapentadol—Constipation—Cyclosporine—psoriasis	0.000166	0.000803	CcSEcCtD
Tapentadol—Dry mouth—Triamcinolone—psoriasis	0.000166	0.000801	CcSEcCtD
Tapentadol—Angioedema—Betamethasone—psoriasis	0.000165	0.000798	CcSEcCtD
Tapentadol—Angioedema—Dexamethasone—psoriasis	0.000165	0.000798	CcSEcCtD
Tapentadol—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000165	0.000796	CcSEcCtD
Tapentadol—Diarrhoea—Mycophenolic acid—psoriasis	0.000164	0.000794	CcSEcCtD
Tapentadol—Angiopathy—Prednisone—psoriasis	0.000164	0.000793	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000163	0.000791	CcSEcCtD
Tapentadol—Immune system disorder—Prednisone—psoriasis	0.000163	0.000789	CcSEcCtD
Tapentadol—Anaphylactic shock—Triamcinolone—psoriasis	0.000162	0.000785	CcSEcCtD
Tapentadol—Oedema—Triamcinolone—psoriasis	0.000162	0.000785	CcSEcCtD
Tapentadol—Vertigo—Betamethasone—psoriasis	0.000162	0.000785	CcSEcCtD
Tapentadol—Vertigo—Dexamethasone—psoriasis	0.000162	0.000785	CcSEcCtD
Tapentadol—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000162	0.00716	CbGpPWpGaD
Tapentadol—Syncope—Betamethasone—psoriasis	0.000162	0.000783	CcSEcCtD
Tapentadol—Syncope—Dexamethasone—psoriasis	0.000162	0.000783	CcSEcCtD
Tapentadol—Constipation—Mycophenolate mofetil—psoriasis	0.000162	0.000783	CcSEcCtD
Tapentadol—Infection—Triamcinolone—psoriasis	0.000161	0.00078	CcSEcCtD
Tapentadol—Hypotension—Hydrocortisone—psoriasis	0.000161	0.00078	CcSEcCtD
Tapentadol—Feeling abnormal—Cyclosporine—psoriasis	0.00016	0.000774	CcSEcCtD
Tapentadol—Shock—Triamcinolone—psoriasis	0.00016	0.000773	CcSEcCtD
Tapentadol—Insomnia—Prednisolone—psoriasis	0.00016	0.000773	CcSEcCtD
Tapentadol—Loss of consciousness—Dexamethasone—psoriasis	0.000159	0.000768	CcSEcCtD
Tapentadol—Loss of consciousness—Betamethasone—psoriasis	0.000159	0.000768	CcSEcCtD
Tapentadol—Dizziness—Mycophenolic acid—psoriasis	0.000159	0.000767	CcSEcCtD
Tapentadol—Paraesthesia—Prednisolone—psoriasis	0.000159	0.000767	CcSEcCtD
Tapentadol—Tachycardia—Triamcinolone—psoriasis	0.000158	0.000767	CcSEcCtD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000158	0.00701	CbGpPWpGaD
Tapentadol—Mental disorder—Prednisone—psoriasis	0.000158	0.000765	CcSEcCtD
Tapentadol—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.000158	0.00697	CbGpPWpGaD
Tapentadol—Malnutrition—Prednisone—psoriasis	0.000157	0.000761	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000157	0.00076	CcSEcCtD
Tapentadol—Hyperhidrosis—Triamcinolone—psoriasis	0.000157	0.000759	CcSEcCtD
Tapentadol—Convulsion—Dexamethasone—psoriasis	0.000156	0.000757	CcSEcCtD
Tapentadol—Convulsion—Betamethasone—psoriasis	0.000156	0.000757	CcSEcCtD
Tapentadol—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000156	0.000755	CcSEcCtD
Tapentadol—Insomnia—Hydrocortisone—psoriasis	0.000156	0.000755	CcSEcCtD
Tapentadol—OPRK1—GPCR ligand binding—HCAR2—psoriasis	0.000156	0.00689	CbGpPWpGaD
Tapentadol—Paraesthesia—Hydrocortisone—psoriasis	0.000155	0.000749	CcSEcCtD
Tapentadol—Urticaria—Cyclosporine—psoriasis	0.000154	0.000746	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—IL10—psoriasis	0.000154	0.0068	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000153	0.00678	CbGpPWpGaD
Tapentadol—Anxiety—Dexamethasone—psoriasis	0.000153	0.000741	CcSEcCtD
Tapentadol—Anxiety—Betamethasone—psoriasis	0.000153	0.000741	CcSEcCtD
Tapentadol—Vomiting—Mycophenolic acid—psoriasis	0.000152	0.000738	CcSEcCtD
Tapentadol—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	0.000152	0.00674	CbGpPWpGaD
Tapentadol—Dyspepsia—Hydrocortisone—psoriasis	0.000152	0.000734	CcSEcCtD
Tapentadol—Rash—Mycophenolic acid—psoriasis	0.000151	0.000732	CcSEcCtD
Tapentadol—Dermatitis—Mycophenolic acid—psoriasis	0.000151	0.000731	CcSEcCtD
Tapentadol—Urticaria—Mycophenolate mofetil—psoriasis	0.00015	0.000727	CcSEcCtD
Tapentadol—Headache—Mycophenolic acid—psoriasis	0.00015	0.000727	CcSEcCtD
Tapentadol—Decreased appetite—Hydrocortisone—psoriasis	0.00015	0.000725	CcSEcCtD
Tapentadol—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.00015	0.00662	CbGpPWpGaD
Tapentadol—Urinary tract disorder—Methotrexate—psoriasis	0.000149	0.000721	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000149	0.00072	CcSEcCtD
Tapentadol—Fatigue—Hydrocortisone—psoriasis	0.000149	0.000719	CcSEcCtD
Tapentadol—Vision blurred—Prednisone—psoriasis	0.000148	0.000717	CcSEcCtD
Tapentadol—Urethral disorder—Methotrexate—psoriasis	0.000148	0.000716	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000148	0.000716	CcSEcCtD
Tapentadol—Anaphylactic shock—Betamethasone—psoriasis	0.000147	0.000713	CcSEcCtD
Tapentadol—Oedema—Dexamethasone—psoriasis	0.000147	0.000713	CcSEcCtD
Tapentadol—Anaphylactic shock—Dexamethasone—psoriasis	0.000147	0.000713	CcSEcCtD
Tapentadol—Oedema—Betamethasone—psoriasis	0.000147	0.000713	CcSEcCtD
Tapentadol—Insomnia—Triamcinolone—psoriasis	0.000147	0.00071	CcSEcCtD
Tapentadol—Infection—Betamethasone—psoriasis	0.000146	0.000708	CcSEcCtD
Tapentadol—Infection—Dexamethasone—psoriasis	0.000146	0.000708	CcSEcCtD
Tapentadol—Paraesthesia—Triamcinolone—psoriasis	0.000146	0.000705	CcSEcCtD
Tapentadol—Feeling abnormal—Prednisolone—psoriasis	0.000145	0.000704	CcSEcCtD
Tapentadol—Visual impairment—Methotrexate—psoriasis	0.000145	0.000704	CcSEcCtD
Tapentadol—Shock—Dexamethasone—psoriasis	0.000145	0.000701	CcSEcCtD
Tapentadol—Shock—Betamethasone—psoriasis	0.000145	0.000701	CcSEcCtD
Tapentadol—Dyspnoea—Triamcinolone—psoriasis	0.000145	0.0007	CcSEcCtD
Tapentadol—Nervous system disorder—Dexamethasone—psoriasis	0.000144	0.000699	CcSEcCtD
Tapentadol—Nervous system disorder—Betamethasone—psoriasis	0.000144	0.000699	CcSEcCtD
Tapentadol—Agitation—Prednisone—psoriasis	0.000144	0.000699	CcSEcCtD
Tapentadol—Tachycardia—Dexamethasone—psoriasis	0.000144	0.000696	CcSEcCtD
Tapentadol—Tachycardia—Betamethasone—psoriasis	0.000144	0.000696	CcSEcCtD
Tapentadol—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000144	0.00636	CbGpPWpGaD
Tapentadol—Angioedema—Prednisone—psoriasis	0.000144	0.000695	CcSEcCtD
Tapentadol—Hypersensitivity—Cyclosporine—psoriasis	0.000143	0.000692	CcSEcCtD
Tapentadol—Dyspepsia—Triamcinolone—psoriasis	0.000143	0.000691	CcSEcCtD
Tapentadol—Nausea—Mycophenolic acid—psoriasis	0.000142	0.000689	CcSEcCtD
Tapentadol—Hyperhidrosis—Betamethasone—psoriasis	0.000142	0.000689	CcSEcCtD
Tapentadol—Hyperhidrosis—Dexamethasone—psoriasis	0.000142	0.000689	CcSEcCtD
Tapentadol—Feeling abnormal—Hydrocortisone—psoriasis	0.000142	0.000687	CcSEcCtD
Tapentadol—Vertigo—Prednisone—psoriasis	0.000141	0.000683	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—psoriasis	0.000141	0.000682	CcSEcCtD
Tapentadol—Syncope—Prednisone—psoriasis	0.000141	0.000682	CcSEcCtD
Tapentadol—Urticaria—Prednisolone—psoriasis	0.00014	0.000679	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—psoriasis	0.00014	0.000678	CcSEcCtD
Tapentadol—Fatigue—Triamcinolone—psoriasis	0.00014	0.000677	CcSEcCtD
Tapentadol—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000139	0.000675	CcSEcCtD
Tapentadol—Asthenia—Cyclosporine—psoriasis	0.000139	0.000673	CcSEcCtD
Tapentadol—Loss of consciousness—Prednisone—psoriasis	0.000138	0.000668	CcSEcCtD
Tapentadol—Hypotension—Betamethasone—psoriasis	0.000138	0.000666	CcSEcCtD
Tapentadol—Hypotension—Dexamethasone—psoriasis	0.000138	0.000666	CcSEcCtD
Tapentadol—Pruritus—Cyclosporine—psoriasis	0.000137	0.000664	CcSEcCtD
Tapentadol—Urticaria—Hydrocortisone—psoriasis	0.000137	0.000663	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—psoriasis	0.000137	0.000662	CcSEcCtD
Tapentadol—Immune system disorder—Methotrexate—psoriasis	0.000136	0.000659	CcSEcCtD
Tapentadol—Convulsion—Prednisone—psoriasis	0.000136	0.000659	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—psoriasis	0.000136	0.000658	CcSEcCtD
Tapentadol—Asthenia—Mycophenolate mofetil—psoriasis	0.000136	0.000657	CcSEcCtD
Tapentadol—Chills—Methotrexate—psoriasis	0.000135	0.000655	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000134	0.000649	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000134	0.000649	CcSEcCtD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000134	0.00592	CbGpPWpGaD
Tapentadol—Pruritus—Mycophenolate mofetil—psoriasis	0.000134	0.000648	CcSEcCtD
Tapentadol—Arthralgia—Prednisone—psoriasis	0.000134	0.000647	CcSEcCtD
Tapentadol—Feeling abnormal—Triamcinolone—psoriasis	0.000134	0.000647	CcSEcCtD
Tapentadol—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	0.000134	0.00591	CbGpPWpGaD
Tapentadol—Anxiety—Prednisone—psoriasis	0.000133	0.000645	CcSEcCtD
Tapentadol—Insomnia—Dexamethasone—psoriasis	0.000133	0.000645	CcSEcCtD
Tapentadol—Insomnia—Betamethasone—psoriasis	0.000133	0.000645	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000133	0.000643	CcSEcCtD
Tapentadol—Diarrhoea—Cyclosporine—psoriasis	0.000133	0.000642	CcSEcCtD
Tapentadol—Paraesthesia—Dexamethasone—psoriasis	0.000132	0.00064	CcSEcCtD
Tapentadol—Paraesthesia—Betamethasone—psoriasis	0.000132	0.00064	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—psoriasis	0.000132	0.00064	CcSEcCtD
Tapentadol—OPRM1—GPCR ligand binding—HCAR2—psoriasis	0.000132	0.00582	CbGpPWpGaD
Tapentadol—Malnutrition—Methotrexate—psoriasis	0.000131	0.000636	CcSEcCtD
Tapentadol—Hypersensitivity—Prednisolone—psoriasis	0.00013	0.000629	CcSEcCtD
Tapentadol—Dyspepsia—Dexamethasone—psoriasis	0.00013	0.000627	CcSEcCtD
Tapentadol—Dyspepsia—Betamethasone—psoriasis	0.00013	0.000627	CcSEcCtD
Tapentadol—SLC6A4—Monoamine Transport—TNF—psoriasis	0.00013	0.00573	CbGpPWpGaD
Tapentadol—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000129	0.000627	CcSEcCtD
Tapentadol—Urticaria—Triamcinolone—psoriasis	0.000129	0.000624	CcSEcCtD
Tapentadol—Dizziness—Cyclosporine—psoriasis	0.000128	0.000621	CcSEcCtD
Tapentadol—Oedema—Prednisone—psoriasis	0.000128	0.000621	CcSEcCtD
Tapentadol—Anaphylactic shock—Prednisone—psoriasis	0.000128	0.000621	CcSEcCtD
Tapentadol—Decreased appetite—Dexamethasone—psoriasis	0.000128	0.00062	CcSEcCtD
Tapentadol—Decreased appetite—Betamethasone—psoriasis	0.000128	0.00062	CcSEcCtD
Tapentadol—Infection—Prednisone—psoriasis	0.000127	0.000617	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Betamethasone—psoriasis	0.000127	0.000615	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000127	0.000615	CcSEcCtD
Tapentadol—Hypersensitivity—Hydrocortisone—psoriasis	0.000127	0.000615	CcSEcCtD
Tapentadol—Fatigue—Betamethasone—psoriasis	0.000127	0.000614	CcSEcCtD
Tapentadol—Fatigue—Dexamethasone—psoriasis	0.000127	0.000614	CcSEcCtD
Tapentadol—Shock—Prednisone—psoriasis	0.000126	0.000611	CcSEcCtD
Tapentadol—Nervous system disorder—Prednisone—psoriasis	0.000126	0.000609	CcSEcCtD
Tapentadol—Tachycardia—Prednisone—psoriasis	0.000125	0.000606	CcSEcCtD
Tapentadol—Dizziness—Mycophenolate mofetil—psoriasis	0.000125	0.000606	CcSEcCtD
Tapentadol—Skin disorder—Prednisone—psoriasis	0.000125	0.000603	CcSEcCtD
Tapentadol—Hyperhidrosis—Prednisone—psoriasis	0.000124	0.0006	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—psoriasis	0.000124	0.000599	CcSEcCtD
Tapentadol—Asthenia—Hydrocortisone—psoriasis	0.000124	0.000599	CcSEcCtD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000124	0.00547	CbGpPWpGaD
Tapentadol—Vomiting—Cyclosporine—psoriasis	0.000123	0.000597	CcSEcCtD
Tapentadol—Rash—Cyclosporine—psoriasis	0.000122	0.000592	CcSEcCtD
Tapentadol—Dermatitis—Cyclosporine—psoriasis	0.000122	0.000591	CcSEcCtD
Tapentadol—Pruritus—Hydrocortisone—psoriasis	0.000122	0.00059	CcSEcCtD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000122	0.00538	CbGpPWpGaD
Tapentadol—Headache—Cyclosporine—psoriasis	0.000122	0.000588	CcSEcCtD
Tapentadol—Feeling abnormal—Dexamethasone—psoriasis	0.000121	0.000587	CcSEcCtD
Tapentadol—Feeling abnormal—Betamethasone—psoriasis	0.000121	0.000587	CcSEcCtD
Tapentadol—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000121	0.00537	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000121	0.00536	CbGpPWpGaD
Tapentadol—Vomiting—Mycophenolate mofetil—psoriasis	0.00012	0.000582	CcSEcCtD
Tapentadol—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.00012	0.00529	CbGpPWpGaD
Tapentadol—Hypersensitivity—Triamcinolone—psoriasis	0.00012	0.000579	CcSEcCtD
Tapentadol—Rash—Mycophenolate mofetil—psoriasis	0.000119	0.000577	CcSEcCtD
Tapentadol—Dermatitis—Mycophenolate mofetil—psoriasis	0.000119	0.000577	CcSEcCtD
Tapentadol—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	0.000119	0.00526	CbGpPWpGaD
Tapentadol—Headache—Mycophenolate mofetil—psoriasis	0.000119	0.000574	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—psoriasis	0.000118	0.000571	CcSEcCtD
Tapentadol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000118	0.00522	CbGpPWpGaD
Tapentadol—Diarrhoea—Hydrocortisone—psoriasis	0.000118	0.000571	CcSEcCtD
Tapentadol—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000118	0.0052	CbGpPWpGaD
Tapentadol—Urticaria—Betamethasone—psoriasis	0.000117	0.000566	CcSEcCtD
Tapentadol—Urticaria—Dexamethasone—psoriasis	0.000117	0.000566	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Prednisone—psoriasis	0.000117	0.000565	CcSEcCtD
Tapentadol—Dizziness—Prednisolone—psoriasis	0.000117	0.000565	CcSEcCtD
Tapentadol—Asthenia—Triamcinolone—psoriasis	0.000116	0.000564	CcSEcCtD
Tapentadol—Insomnia—Prednisone—psoriasis	0.000116	0.000561	CcSEcCtD
Tapentadol—Nausea—Cyclosporine—psoriasis	0.000115	0.000558	CcSEcCtD
Tapentadol—Paraesthesia—Prednisone—psoriasis	0.000115	0.000557	CcSEcCtD
Tapentadol—Pruritus—Triamcinolone—psoriasis	0.000115	0.000556	CcSEcCtD
Tapentadol—Cough—Methotrexate—psoriasis	0.000115	0.000555	CcSEcCtD
Tapentadol—Dizziness—Hydrocortisone—psoriasis	0.000114	0.000552	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—psoriasis	0.000114	0.000551	CcSEcCtD
Tapentadol—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	0.000113	0.005	CbGpPWpGaD
Tapentadol—Dyspepsia—Prednisone—psoriasis	0.000113	0.000546	CcSEcCtD
Tapentadol—Nausea—Mycophenolate mofetil—psoriasis	0.000112	0.000544	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—psoriasis	0.000112	0.000541	CcSEcCtD
Tapentadol—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000112	0.00494	CbGpPWpGaD
Tapentadol—Decreased appetite—Prednisone—psoriasis	0.000112	0.00054	CcSEcCtD
Tapentadol—SLC6A2—Monoamine Transport—TNF—psoriasis	0.000111	0.00493	CbGpPWpGaD
Tapentadol—Rash—Prednisolone—psoriasis	0.000111	0.000539	CcSEcCtD
Tapentadol—Dermatitis—Prednisolone—psoriasis	0.000111	0.000538	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000111	0.000537	CcSEcCtD
Tapentadol—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000111	0.00489	CbGpPWpGaD
Tapentadol—Fatigue—Prednisone—psoriasis	0.000111	0.000535	CcSEcCtD
Tapentadol—Headache—Prednisolone—psoriasis	0.000111	0.000535	CcSEcCtD
Tapentadol—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.00011	0.00487	CbGpPWpGaD
Tapentadol—Constipation—Prednisone—psoriasis	0.00011	0.000531	CcSEcCtD
Tapentadol—Vomiting—Hydrocortisone—psoriasis	0.00011	0.00053	CcSEcCtD
Tapentadol—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000109	0.00483	CbGpPWpGaD
Tapentadol—Rash—Hydrocortisone—psoriasis	0.000109	0.000526	CcSEcCtD
Tapentadol—Dermatitis—Hydrocortisone—psoriasis	0.000109	0.000525	CcSEcCtD
Tapentadol—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000108	0.00479	CbGpPWpGaD
Tapentadol—Confusional state—Methotrexate—psoriasis	0.000108	0.000523	CcSEcCtD
Tapentadol—Headache—Hydrocortisone—psoriasis	0.000108	0.000523	CcSEcCtD
Tapentadol—Dizziness—Triamcinolone—psoriasis	0.000107	0.000519	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—psoriasis	0.000107	0.000519	CcSEcCtD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000107	0.00473	CbGpPWpGaD
Tapentadol—Infection—Methotrexate—psoriasis	0.000107	0.000515	CcSEcCtD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000106	0.0047	CbGpPWpGaD
Tapentadol—Feeling abnormal—Prednisone—psoriasis	0.000106	0.000511	CcSEcCtD
Tapentadol—Asthenia—Betamethasone—psoriasis	0.000106	0.000511	CcSEcCtD
Tapentadol—Asthenia—Dexamethasone—psoriasis	0.000106	0.000511	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—psoriasis	0.000105	0.000509	CcSEcCtD
Tapentadol—Nausea—Prednisolone—psoriasis	0.000105	0.000507	CcSEcCtD
Tapentadol—Pruritus—Betamethasone—psoriasis	0.000104	0.000504	CcSEcCtD
Tapentadol—Pruritus—Dexamethasone—psoriasis	0.000104	0.000504	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—psoriasis	0.000104	0.000504	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—psoriasis	0.000104	0.000501	CcSEcCtD
Tapentadol—Vomiting—Triamcinolone—psoriasis	0.000103	0.000499	CcSEcCtD
Tapentadol—Nausea—Hydrocortisone—psoriasis	0.000102	0.000496	CcSEcCtD
Tapentadol—Rash—Triamcinolone—psoriasis	0.000102	0.000495	CcSEcCtD
Tapentadol—Dermatitis—Triamcinolone—psoriasis	0.000102	0.000495	CcSEcCtD
Tapentadol—Urticaria—Prednisone—psoriasis	0.000102	0.000493	CcSEcCtD
Tapentadol—Headache—Triamcinolone—psoriasis	0.000102	0.000492	CcSEcCtD
Tapentadol—Diarrhoea—Betamethasone—psoriasis	0.000101	0.000488	CcSEcCtD
Tapentadol—Diarrhoea—Dexamethasone—psoriasis	0.000101	0.000488	CcSEcCtD
Tapentadol—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	0.0001	0.00444	CbGpPWpGaD
Tapentadol—Hypotension—Methotrexate—psoriasis	0.0001	0.000485	CcSEcCtD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	9.89e-05	0.00438	CbGpPWpGaD
Tapentadol—Musculoskeletal discomfort—Methotrexate—psoriasis	9.77e-05	0.000473	CcSEcCtD
Tapentadol—Dizziness—Dexamethasone—psoriasis	9.74e-05	0.000471	CcSEcCtD
Tapentadol—Dizziness—Betamethasone—psoriasis	9.74e-05	0.000471	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—psoriasis	9.7e-05	0.000469	CcSEcCtD
Tapentadol—Nausea—Triamcinolone—psoriasis	9.64e-05	0.000467	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—psoriasis	9.63e-05	0.000466	CcSEcCtD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	9.59e-05	0.00424	CbGpPWpGaD
Tapentadol—Dyspnoea—Methotrexate—psoriasis	9.56e-05	0.000462	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—psoriasis	9.53e-05	0.000461	CcSEcCtD
Tapentadol—Hypersensitivity—Prednisone—psoriasis	9.45e-05	0.000457	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—psoriasis	9.44e-05	0.000457	CcSEcCtD
Tapentadol—HTR3A—Transmembrane transport of small molecules—CP—psoriasis	9.37e-05	0.00414	CbGpPWpGaD
Tapentadol—Vomiting—Betamethasone—psoriasis	9.37e-05	0.000453	CcSEcCtD
Tapentadol—Vomiting—Dexamethasone—psoriasis	9.37e-05	0.000453	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—psoriasis	9.32e-05	0.000451	CcSEcCtD
Tapentadol—Rash—Betamethasone—psoriasis	9.29e-05	0.000449	CcSEcCtD
Tapentadol—Rash—Dexamethasone—psoriasis	9.29e-05	0.000449	CcSEcCtD
Tapentadol—Dermatitis—Betamethasone—psoriasis	9.28e-05	0.000449	CcSEcCtD
Tapentadol—Dermatitis—Dexamethasone—psoriasis	9.28e-05	0.000449	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—psoriasis	9.26e-05	0.000448	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—psoriasis	9.24e-05	0.000447	CcSEcCtD
Tapentadol—OPRD1—GPCR ligand binding—CCL20—psoriasis	9.23e-05	0.00408	CbGpPWpGaD
Tapentadol—Headache—Dexamethasone—psoriasis	9.23e-05	0.000446	CcSEcCtD
Tapentadol—Headache—Betamethasone—psoriasis	9.23e-05	0.000446	CcSEcCtD
Tapentadol—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	9.22e-05	0.00408	CbGpPWpGaD
Tapentadol—Asthenia—Prednisone—psoriasis	9.2e-05	0.000445	CcSEcCtD
Tapentadol—OPRD1—Signaling by GPCR—HCAR2—psoriasis	9.12e-05	0.00403	CbGpPWpGaD
Tapentadol—Pruritus—Prednisone—psoriasis	9.08e-05	0.000439	CcSEcCtD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.98e-05	0.00397	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—CARM1—psoriasis	8.94e-05	0.00395	CbGpPWpGaD
Tapentadol—Feeling abnormal—Methotrexate—psoriasis	8.83e-05	0.000427	CcSEcCtD
Tapentadol—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	8.8e-05	0.00389	CbGpPWpGaD
Tapentadol—Diarrhoea—Prednisone—psoriasis	8.78e-05	0.000425	CcSEcCtD
Tapentadol—Nausea—Betamethasone—psoriasis	8.75e-05	0.000423	CcSEcCtD
Tapentadol—Nausea—Dexamethasone—psoriasis	8.75e-05	0.000423	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—psoriasis	8.52e-05	0.000412	CcSEcCtD
Tapentadol—Dizziness—Prednisone—psoriasis	8.48e-05	0.00041	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.4e-05	0.00372	CbGpPWpGaD
Tapentadol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.23e-05	0.00364	CbGpPWpGaD
Tapentadol—Vomiting—Prednisone—psoriasis	8.16e-05	0.000395	CcSEcCtD
Tapentadol—OPRK1—GPCR ligand binding—CCL20—psoriasis	8.09e-05	0.00358	CbGpPWpGaD
Tapentadol—Rash—Prednisone—psoriasis	8.09e-05	0.000391	CcSEcCtD
Tapentadol—Dermatitis—Prednisone—psoriasis	8.08e-05	0.000391	CcSEcCtD
Tapentadol—Headache—Prednisone—psoriasis	8.04e-05	0.000389	CcSEcCtD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	8.01e-05	0.00354	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HCAR2—psoriasis	8e-05	0.00354	CbGpPWpGaD
Tapentadol—Hypersensitivity—Methotrexate—psoriasis	7.9e-05	0.000382	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—JUN—psoriasis	7.81e-05	0.00346	CbGpPWpGaD
Tapentadol—Asthenia—Methotrexate—psoriasis	7.69e-05	0.000372	CcSEcCtD
Tapentadol—Nausea—Prednisone—psoriasis	7.62e-05	0.000369	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—psoriasis	7.58e-05	0.000367	CcSEcCtD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.52e-05	0.00333	CbGpPWpGaD
Tapentadol—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	7.5e-05	0.00332	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	7.44e-05	0.00329	CbGpPWpGaD
Tapentadol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	7.34e-05	0.00325	CbGpPWpGaD
Tapentadol—Diarrhoea—Methotrexate—psoriasis	7.34e-05	0.000355	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—psoriasis	7.09e-05	0.000343	CcSEcCtD
Tapentadol—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7e-05	0.00309	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CCL20—psoriasis	6.84e-05	0.00302	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—CD4—psoriasis	6.83e-05	0.00302	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.83e-05	0.00302	CbGpPWpGaD
Tapentadol—Vomiting—Methotrexate—psoriasis	6.82e-05	0.00033	CcSEcCtD
Tapentadol—Rash—Methotrexate—psoriasis	6.76e-05	0.000327	CcSEcCtD
Tapentadol—OPRM1—Signaling by GPCR—HCAR2—psoriasis	6.76e-05	0.00299	CbGpPWpGaD
Tapentadol—Dermatitis—Methotrexate—psoriasis	6.75e-05	0.000327	CcSEcCtD
Tapentadol—Headache—Methotrexate—psoriasis	6.72e-05	0.000325	CcSEcCtD
Tapentadol—SLC6A4—Circadian rythm related genes—LEP—psoriasis	6.44e-05	0.00285	CbGpPWpGaD
Tapentadol—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.43e-05	0.00285	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NDUFA5—psoriasis	6.39e-05	0.00283	CbGpPWpGaD
Tapentadol—Nausea—Methotrexate—psoriasis	6.37e-05	0.000308	CcSEcCtD
Tapentadol—OPRM1—TCR Signaling Pathway—JUN—psoriasis	6.11e-05	0.0027	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	6e-05	0.00266	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	5.88e-05	0.0026	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—TNF—psoriasis	5.85e-05	0.00259	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	5.61e-05	0.00248	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP2S1—psoriasis	5.43e-05	0.0024	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HCAR2—psoriasis	5.39e-05	0.00238	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.24e-05	0.00232	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CCL20—psoriasis	5.22e-05	0.00231	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NDUFA5—psoriasis	5.19e-05	0.0023	CbGpPWpGaD
Tapentadol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	5.06e-05	0.00224	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	5.03e-05	0.00222	CbGpPWpGaD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.88e-05	0.00216	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	4.88e-05	0.00216	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.84e-05	0.00214	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.8e-05	0.00212	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CCL20—psoriasis	4.74e-05	0.00209	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HCAR2—psoriasis	4.72e-05	0.00209	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—IL6—psoriasis	4.72e-05	0.00209	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.69e-05	0.00208	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TAGAP—psoriasis	4.67e-05	0.00207	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CCL20—psoriasis	4.57e-05	0.00202	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP2S1—psoriasis	4.41e-05	0.00195	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	4.28e-05	0.00189	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.26e-05	0.00188	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CCL20—psoriasis	4.15e-05	0.00184	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	4.12e-05	0.00182	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TAGAP—psoriasis	4.1e-05	0.00181	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HCAR2—psoriasis	3.99e-05	0.00177	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—JUN—psoriasis	3.98e-05	0.00176	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CCL20—psoriasis	3.86e-05	0.00171	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—IL6—psoriasis	3.69e-05	0.00163	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	3.65e-05	0.00161	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.62e-05	0.0016	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	3.61e-05	0.0016	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CCL20—psoriasis	3.51e-05	0.00155	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TAGAP—psoriasis	3.46e-05	0.00153	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.27e-05	0.00145	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	3.05e-05	0.00135	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	2.95e-05	0.0013	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.87e-05	0.00127	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCL20—psoriasis	2.8e-05	0.00124	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CARM1—psoriasis	2.65e-05	0.00117	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—psoriasis	2.63e-05	0.00116	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CXCL8—psoriasis	2.49e-05	0.0011	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCL20—psoriasis	2.45e-05	0.00108	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NDUFA5—psoriasis	2.44e-05	0.00108	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.43e-05	0.00107	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—IL6—psoriasis	2.41e-05	0.00106	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.31e-05	0.00102	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.28e-05	0.00101	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NDUFA5—psoriasis	2.24e-05	0.000993	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NDUFA5—psoriasis	2.23e-05	0.000984	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CXCL8—psoriasis	2.19e-05	0.000966	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CARM1—psoriasis	2.16e-05	0.000954	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP2S1—psoriasis	2.07e-05	0.000918	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.07e-05	0.000918	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCL20—psoriasis	2.07e-05	0.000917	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.02e-05	0.000891	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2S1—psoriasis	1.91e-05	0.000844	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2S1—psoriasis	1.89e-05	0.000837	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CXCL8—psoriasis	1.85e-05	0.000817	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CAT—psoriasis	1.63e-05	0.000722	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.54e-05	0.000681	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.47e-05	0.00065	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.41e-05	0.000623	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.35e-05	0.000597	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CAT—psoriasis	1.33e-05	0.000587	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.29e-05	0.00057	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.28e-05	0.000566	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—APOE—psoriasis	1.27e-05	0.000561	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1.23e-05	0.000546	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.14e-05	0.000505	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—LEP—psoriasis	1.14e-05	0.000503	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APOE—psoriasis	1.14e-05	0.000503	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.12e-05	0.000496	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PPARG—psoriasis	1.1e-05	0.000488	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.09e-05	0.000481	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.09e-05	0.000481	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.06e-05	0.000469	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.04e-05	0.000462	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—APOE—psoriasis	1.03e-05	0.000456	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CARM1—psoriasis	1.01e-05	0.000448	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APOE—psoriasis	9.97e-06	0.000441	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LEP—psoriasis	9.97e-06	0.000441	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.92e-06	0.000439	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL8—psoriasis	9.48e-06	0.000419	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.47e-06	0.000419	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CARM1—psoriasis	9.32e-06	0.000412	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NFKBIA—psoriasis	9.29e-06	0.000411	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CARM1—psoriasis	9.24e-06	0.000409	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARG—psoriasis	8.98e-06	0.000397	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TYK2—psoriasis	8.68e-06	0.000384	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.64e-06	0.000382	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LEP—psoriasis	8.43e-06	0.000373	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOE—psoriasis	8.43e-06	0.000373	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFKBIA—psoriasis	7.85e-06	0.000347	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TYK2—psoriasis	7.61e-06	0.000337	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—psoriasis	7.55e-06	0.000334	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—psoriasis	7.18e-06	0.000318	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—psoriasis	7.02e-06	0.000311	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NFKB1—psoriasis	6.76e-06	0.000299	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—psoriasis	6.62e-06	0.000293	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TYK2—psoriasis	6.43e-06	0.000284	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—psoriasis	6.3e-06	0.000279	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAT—psoriasis	6.23e-06	0.000276	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—psoriasis	6.16e-06	0.000272	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—psoriasis	6.14e-06	0.000271	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—psoriasis	6.08e-06	0.000269	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NFKB1—psoriasis	5.93e-06	0.000262	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAT—psoriasis	5.73e-06	0.000254	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAT—psoriasis	5.68e-06	0.000251	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—psoriasis	5.6e-06	0.000248	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—psoriasis	5.38e-06	0.000238	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—psoriasis	5.33e-06	0.000236	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—psoriasis	5.32e-06	0.000235	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—psoriasis	5.21e-06	0.00023	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFKB1—psoriasis	5.01e-06	0.000222	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOE—psoriasis	4.84e-06	0.000214	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—psoriasis	4.64e-06	0.000205	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—psoriasis	4.55e-06	0.000201	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—psoriasis	4.5e-06	0.000199	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOE—psoriasis	4.45e-06	0.000197	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOE—psoriasis	4.42e-06	0.000195	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—psoriasis	4.24e-06	0.000188	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARG—psoriasis	4.22e-06	0.000187	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—psoriasis	4.07e-06	0.00018	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARG—psoriasis	3.88e-06	0.000172	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARG—psoriasis	3.85e-06	0.00017	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—psoriasis	3.72e-06	0.000165	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—psoriasis	3.44e-06	0.000152	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—psoriasis	3.15e-06	0.000139	CbGpPWpGaD
